Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 55 results.
User Information
Export Records
  1. 1.   Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC
  2. Stravokefalou, Vasiliki; Stellas, Dimitris; Karaliota,Sevasti; Nagy,Bethany; Valentin, Antonio; Bergamaschi, Cristina; Dimas, Konstantinos; Pavlakis,George
  3. Frontiers in Immunology. 2022, Jan 13; 13: 1014802.
  1. 2.   Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
  2. Coyne, Geraldine O 'Sullivan; Wang,Lihua; Zlott, Jennifer; Juwara,Lamin; Covey, Joseph M; Beumer, Jan H; Cristea, Mihaela C; Newman, Edward M; Koehler, Stephen; Nieva, Jorge J; Garcia, Agustin A; Gandara, David R; Miller,Brandon; Khin,Sonny; Miller, Sarah B; Steinberg, Seth M; Rubinstein, Larry; Parchment,Ralph; Kinders,Robert; Piekarz, Richard L; Kummar, Shivaani; Chen, Alice P; Doroshow, James H
  3. Cancer chemotherapy and pharmacology. 2020, Apr 20;
  1. 3.   Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration
  2. Ward, Yvona; Lake, Ross; Faraji, Farhoud; Sperger, Jamie; Martin, Philip; Gilliard, Cameron; Ku, Kimberly P; Rodems, Tamara; Niles, David; Tillman, Heather; Yin, JuanJuan; Hunter, Kent; Sowalsky, Adam G; Lang, Joshua; Kelly, Kathleen
  3. Cell Reports. 2018, Apr 17; 23(3): 808-822.
  1. 4.   In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines
  2. Behrsing, H. P.; Furniss, M. J.; Robillard, K. A.; Tomaszewski, J. E.; Parchment, R. E.
  3. Cancer Chemotherapy and Pharmacology. 2010, May; 65(6): 1083-1091.
  1. 5.   Cell-specific responses to loss of cyclin-dependent kinases
  2. Berthet, C.; Kaldis, P.
  3. Oncogene. 2007, Jul; 26(31): 4469-4477.
  1. 6.   Targeting hypoxia cell signaling for cancer therapy
  2. Melillo, G.
  3. Cancer and Metastasis Reviews. 2007, Jun; 26(2): 341-352.
  1. 7.   Crinamine from Crinum asiaticum var.japonicum inhibits hypoxia inducible factor-1 activity but not activity of hypoxia inducible factor-2
  2. Kim, Y. H.; Park, E. J.; Park, M. H.; Badarch, U.; Woldemichael, G. M.; Beutler, J. A.
  3. Biological & Pharmaceutical Bulletin. 2006, Oct; 29(10): 2140-2142.
  1. 8.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 9.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 10.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 11.   An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model
  2. Reilly, K. M.; Broman, K. W.; Bronson, R. T.; Tsang, S.; Loisel, D. A.; Christy, E. S.; Sun, Z. H.; Diehl, J.; Munroe, D. J.; Tuskan, R. G.
  3. Cancer Research. 2006, JAN 1; 66(1): 62-68.
  1. 12.   Evaluating chemical structure similarity as an indicator of cellular growth inhibition
  2. Wallqvist, A.; Huang, R. L.; Thanki, N.; Covell, D. G.
  3. Journal of Chemical Information and Modeling. 2006, JAN-FEB; 46(1): 430-437.
  1. 13.   WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway
  2. Kosakowska-Cholody, T.; Cholody, W. M.; Monks, A.; Woynarowska, B. A.; Michejda, C. J.
  3. Molecular Cancer Therapeutics. 2005, OCT; 4(10): 1617-1627.
  1. 14.   Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity
  2. Carlos, C. A.; Dong, H. F.; Howard, O. M. Z.; Oppenheim, J. J.; Hanisch, F. G.; Finn, O. J.
  3. Journal of Immunology. 2005, AUG 1; 175(3): 1628-1635.
  1. 15.   Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine
  2. Dote, H.; Cerna, D.; Burgan, W. E.; Carter, D. J.; Cerra, M. A.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J.
  3. Clinical Cancer Research. 2005, JUN 15; 11(12): 4571-4579.
  1. 16.   Efficient killing of CD22(+) tumor cells by a humanized diabody-RNase fusion protein
  2. Krauss, J.; Arndt, M. A. E.; Vu, B. K.; Newton, D. L.; Seeber, S.; Rybak, S. M.
  3. Biochemical and Biophysical Research Communications. 2005, JUN 3; 331(2): 595-602.
  1. 17.   Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: A clinical and molecular genetic investigation
  2. Matyakhina, L.; Freedman, R. J.; Bourdeau, I.; Wei, M. H.; Stergiopoulos, S. G.; Chidakel, A.; Walther, M.; bu-Asab, M.; Tsokos, M.; Keil, M.; Toro, J.; Linehan, W. M.; Stratakis, C. A.
  3. Journal of Clinical Endocrinology & Metabolism. 2005, JUN; 90(6): 3773-3779.
  1. 18.   Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation
  2. Hodge, D. R.; Peng, B.; Cherry, J. C.; Hurt, E. M.; Fox, S. D.; Kelley, J. A.; Munroe, D. J.; Farrar, W. L.
  3. Cancer Research. 2005, JUN 1; 65(11): 4673-4682.
  1. 19.   Transduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity
  2. Hu, J. Y.; Li, G. C.; Tong, Y. Q.; Li, Y. H.; Zhou, G. H.; He, X. J.; Xie, P. L.; Wang, J. M.; Sun, Q. B.
  3. International Immunopharmacology. 2005, JUN; 5(6): 971-980.
  1. 20.   Formylpeptide receptor FPR and the rapid growth of malignant human gliomas
  2. Zhou, Y.; Bian, X. W.; Le, Y. Y.; Gong, W. H.; Hu, J. Y.; Zhang, X.; Wang, L. H.; Iribarren, P.; Salcedo, R.; Howard, O. M. Z.; Farrar, W.; Wang, J. M.
  3. Journal of the National Cancer Institute. 2005, JUN 1; 97(11): 823-835.
  1. 21.   Constitutive expression of functional CD40 on mouse renal cancer cells: Induction of Fas and Fas-mediated killing by CD40L
  2. Lee, J. K.; Seki, N.; Sayers, T. J.; Subleski, J.; Gruys, E. M.; Murphy, W. J.; Wiltrout, R. H.
  3. Cellular Immunology. 2005, JUN; 235(2): 145-152.
  1. 22.   Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases
  2. Covell, D. G.; Wallqvist, A.; Huang, R. L.; Thanki, N.; Rabow, A. A.; Lu, X. J.
  3. Proteins-Structure Function and Bioinformatics. 2005, MAY 15; 59(3): 403-433.
  1. 23.   The proteasome inhibitor bortezomib sensitizes human tumor cells to TRAIL-mediated apoptosis
  2. Sayers, T. J.; Brooks, A. D.; Ramirez, T.; Elliott, P. J.; Murphy, W. J.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 641-641.
  1. 24.   A dimeric angiogenin immunofusion protein mediates selective toxicity towards CD22(+) tumor cells
  2. Arndt, M. A. E.; Krauss, J.; Vu, B. K.; Newton, D. L.; Rybak, S. M.
  3. Journal of Immunotherapy. 2005, MAY-JUN; 28(3): 245-251.
  1. 25.   Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers
  2. Arndt, M. A. E.; Krauss, R.; Rybak, S. M.
  3. Febs Letters. 2004, DEC 17; 578(3): 257-261.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel